BOOK
A Global Perspective/Health Inequity in Heart Failure, An Issue of Heart Failure Clinics, E-Book
(2016)
Additional Information
Book Details
Abstract
This special issue of Heart Failure Clinics examines heart failure with a truly global perspective, exposing health inequities in the treatment of heart failure.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| A Global Perspective/HealthInequity in Heart Failure \r | i | ||
| Copyright\r | i | ||
| Contributors | iii | ||
| CONSULTING EDITORS | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword: Heart Failure: A Global Pandemic and Not Just a Disease of the West\r | vii | ||
| Socioeconomic Inequalities in Heart Failure\r | vii | ||
| Heart Failure in Rural Communities\r | vii | ||
| Inequalities in the Access to Advanced Therapy in Heart Failure\r | vii | ||
| Gaps and Resemblances in Current Heart Failure Guidelines: A Clinical Perspective\r | vii | ||
| Prognostic Factors in Hospitalization for Heart Failure in Asia\r | viii | ||
| Biomarkers for Heart Failure in Asia\r | viii | ||
| Heart Transplant in Asia\r | viii | ||
| Epidemiology of Heart Failure in Asia\r | viii | ||
| Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Fail .\r | ix | ||
| Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations\r | ix | ||
| The Impact of Worsening Heart Failure in the United States\r | ix | ||
| End-of-life Heart Failure Care in the United States\r | ix | ||
| Epidemiology of Heart Failure in Europe\r | x | ||
| Acute Heart Failure Syndromes in the Elderly: The European Perspective\r | x | ||
| Characteristics of Intensive Care in Patients Hospitalized for Heart Failure in Europe\r | x | ||
| HEART FAILURE CLINICS\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| January 2016 | xi | ||
| April 2016 | xi | ||
| RECENT ISSUES | xi | ||
| July 2015 | xi | ||
| April 2015 | xi | ||
| Preface: Heart Failure: A Global Pandemic and Not Just a Disease of the West\r | xiii | ||
| Socioeconomic Inequalities in Heart Failure | 507 | ||
| Key points | 507 | ||
| BACKGROUND | 507 | ||
| SOCIOECONOMIC STATUS AND HEART FAILURE | 508 | ||
| EDUCATIONAL LEVEL AND OCCUPATION | 508 | ||
| HEALTH LITERACY AND HEART FAILURE | 509 | ||
| BRIDGING THE GAPS IN SOCIOECONOMIC INEQUALITY | 510 | ||
| FUTURE DIRECTIONS | 511 | ||
| SUMMARY | 511 | ||
| REFERENCES | 511 | ||
| Heart Failure in Rural Communities | 515 | ||
| Key points | 515 | ||
| BACKGROUND | 515 | ||
| EPIDEMIOLOGY | 516 | ||
| ORGANIZATIONAL FACTORS IN RURAL HEALTH SYSTEMS | 517 | ||
| Health System Policies | 517 | ||
| Health Care Providers’ Adherence to Guidelines in the Rural Setting | 517 | ||
| PATIENT-RELATED FACTORS IN RURAL COMMUNITIES | 518 | ||
| ROLE OF INTERVENTIONS TO IMPROVE CHRONIC HEART FAILURE OUTCOMES IN RURAL COMMUNITIES | 518 | ||
| Simplified Diagnostic Approach | 518 | ||
| Telemedicine Support | 518 | ||
| Patient Education | 519 | ||
| Primary Health Care Provider Education and Training | 519 | ||
| SUMMARY | 519 | ||
| REFERENCES | 520 | ||
| Inequalities in the Access to Advanced Therapy in Heart Failure | 523 | ||
| Key points | 523 | ||
| INTRODUCTION | 523 | ||
| SOME DEFINITIONS | 523 | ||
| Developing Countries | 523 | ||
| The Chilean Health Care Model, as a Model of a Developing Country | 524 | ||
| Defining Advanced Heart Failure | 524 | ||
| GENERAL APPROACH TO ADVANCED THERAPIES AND INTRODUCTION TO THE PROBLEM OF INEQUALITIES | 524 | ||
| Cardiac Resynchronization Therapy and Implantable Cardioverter-Defibrillators | 524 | ||
| Mechanical Cardiac Support | 525 | ||
| Heart Transplant | 526 | ||
| OTHER FACTORS THAT MAKE DIFFICULT THE ACCESS TO ADVANCED THERAPIES | 526 | ||
| Economic Issues | 526 | ||
| Access to Health Care | 526 | ||
| Low Number of Heart Failure Specialists | 527 | ||
| SUMMARY | 527 | ||
| REFERENCES | 527 | ||
| Gaps and Resemblances in Current Heart Failure Guidelines | 529 | ||
| Key points | 529 | ||
| INTRODUCTION | 529 | ||
| GRADING THE EVIDENCE AND CLASSIFYING THE RECOMMENDATIONS | 529 | ||
| DEFINITIONS AND TYPES OF HEART FAILURE | 531 | ||
| PHARMACOLOGIC TREATMENT IN HEART FAILURE | 532 | ||
| Angiotensin I–Converting Enzyme Inhibitors | 532 | ||
| Angiotensin Receptor Blockers | 532 | ||
| Mineralocorticoid Receptor Antagonists | 533 | ||
| β-Blockers | 534 | ||
| Digoxin | 535 | ||
| Hydralazine and Isosorbide | 535 | ||
| Oral Anticoagulants | 536 | ||
| NOVEL TREATMENTS | 536 | ||
| Ivabradine | 536 | ||
| Angiotensin Receptor–Neprilysin Inhibitors | 536 | ||
| DEVICE RECOMMENDATIONS IN HEART FAILURE | 536 | ||
| Cardiac Resynchronization Therapy | 536 | ||
| Implantable Cardioverter-Defibrillators for Primary Prevention | 538 | ||
| SUMMARY | 538 | ||
| REFERENCES | 538 | ||
| Prognostic Factors in Hospitalization for Heart Failure in Asia | 543 | ||
| Key points | 543 | ||
| INTRODUCTION | 543 | ||
| PROGNOSTIC FACTORS OF MORTALITY AND MORBIDITY | 544 | ||
| Age | 544 | ||
| Hyponatremia | 545 | ||
| Systolic Blood Pressure | 545 | ||
| Renal Dysfunction | 546 | ||
| Left Ventricular Function | 546 | ||
| Ventricular Conduction Disturbance | 546 | ||
| Anemia | 546 | ||
| Evidence-based Medication Adherence | 547 | ||
| Hospitalization | 547 | ||
| EMERGING PROGNOSTIC FACTORS | 547 | ||
| Hemoconcentration | 547 | ||
| OTHER PROGNOSTIC FACTORS | 547 | ||
| SUMMARY | 548 | ||
| REFERENCES | 548 | ||
| Biomarkers for Heart Failure in Asia | 551 | ||
| Key points | 551 | ||
| INTRODUCTION | 551 | ||
| KEY PLAYERS | 551 | ||
| JAPAN AND THE NATRIURETIC PEPTIDE STORY | 552 | ||
| THE HONG KONG HERITAGE IN BIOMARKERS FOR HEART FAILURE | 553 | ||
| NEW DEVELOPMENTS FROM ASIA IN BIOMARKERS FOR HEART FAILURE | 553 | ||
| Peptide Biomarkers for Heart Failure in Asia | 553 | ||
| News on Nonpeptide Markers from Asia | 555 | ||
| Nucleic Acids as Biomarkers in Heart Failure | 555 | ||
| Genotyping for Heart Failure in Asia | 556 | ||
| Asia Is Organizing | 557 | ||
| Markers When East Meets West | 557 | ||
| REFERENCES | 558 | ||
| Heart Transplant in Asia | 563 | ||
| Key points | 563 | ||
| INTRODUCTION | 563 | ||
| HEART FAILURE IN ASIA | 563 | ||
| Prevalence of Heart Failure | 563 | ||
| Patients’ Characteristics of Heart Failure in Asia | 564 | ||
| Advanced Heart Failure in Asia | 564 | ||
| Heart Failure Management in Asia | 564 | ||
| Heart Failure Outcome in Asia | 564 | ||
| HEART TRANSPLANT IN ASIA | 564 | ||
| History | 564 | ||
| Incidence and Prevalence | 565 | ||
| Recipient and Cause of End-Stage Heart Disease | 565 | ||
| Screening for Donors | 565 | ||
| Survival | 567 | ||
| HEART TRANSPLANT IN SPECIAL SITUATIONS | 568 | ||
| Rheumatic Heart Disease | 568 | ||
| Elderly | 568 | ||
| Hepatitis B Virus Infection | 568 | ||
| POST–HEART TRANSPLANT CARE | 568 | ||
| Immunosuppression and Rejection | 568 | ||
| Endomyocardial Biopsy | 568 | ||
| HEART TRANSPLANT COMPLICATION | 568 | ||
| Primary Graft Failure | 568 | ||
| Cardiac Allograft Vasculopathy | 568 | ||
| Cardiac Arrhythmia | 568 | ||
| Malignancy | 569 | ||
| Infection | 569 | ||
| Mechanical Circulatory Support Devices in Asia | 569 | ||
| Barriers and Key to Success in Heart Transplant Program in Asia | 569 | ||
| Law | 569 | ||
| Ethical Issue | 569 | ||
| Infrastructure | 569 | ||
| Donor Shortage | 569 | ||
| Limitation of Data | 570 | ||
| Future | 570 | ||
| SUMMARY | 570 | ||
| REFERENCES | 570 | ||
| Epidemiology of Heart Failure in Asia | 573 | ||
| Key points | 573 | ||
| INTRODUCTION | 573 | ||
| IMPORTANT ISSUES FOR EPIDEMIOLOGIC COMPARISON | 573 | ||
| Definitions of Heart Failure in Registries of Patients Hospitalized for Heart Failure | 573 | ||
| Site Selection | 574 | ||
| The Time Frame | 574 | ||
| Ethnic Differences | 575 | ||
| EPIDEMIOLOGIC COMPARISON OF PATIENTS HOSPITALIZED FOR HEART FAILURE IN ASIA | 575 | ||
| Patient Characteristics | 575 | ||
| Management | 575 | ||
| Outcome | 577 | ||
| SUMMARY | 578 | ||
| REFERENCES | 578 | ||
| Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America | 581 | ||
| Key points | 581 | ||
| INTRODUCTION | 582 | ||
| BARRIER: POOR VISIBILITY OF CARDIOVASCULAR DISEASE AND CLINICAL TRIALS WITHIN THE INSTITUTION AND THE BROADER COMMUNITY | 582 | ||
| BARRIER: INABILITY OF STUDY SPONSORS TO IDENTIFY SITES CAPABLE OF ENROLLING HIGH VOLUME AND QUALITY PATIENTS | 583 | ||
| BARRIER: TIME-CONSUMING STUDY PROTOCOLS THAT DO NOT REFLECT THE DAY-TO-DAY REALITIES OF PATIENT CARE | 584 | ||
| BARRIER: INADEQUATE INFRASTRUCTURE FOR RECRUITMENT OF PARTICIPANTS AND STUDY CONDUCT | 586 | ||
| BARRIER: UNDERDEVELOPED RELATIONSHIPS BETWEEN CARDIOLOGISTS AND OTHER PHYSICIANS CARING FOR THE CARDIAC PATIENT | 587 | ||
| BARRIER: MISALIGNMENT OF INCENTIVES BETWEEN PRINCIPLE INVESTIGATORS AND PARENT CLINICAL FACILITY | 587 | ||
| BARRIER: LIMITED UPFRONT TRAINING AND ONGOING SUPPORT FOR STUDY COORDINATORS AND OTHER STAFF | 588 | ||
| SUMMARY | 588 | ||
| REFERENCES | 588 | ||
| Hospitalized Heart Failure in the United States | 591 | ||
| Key points | 591 | ||
| UNITED STATES STUDY ENROLLMENT | 592 | ||
| PATIENT CHARACTERISTICS | 593 | ||
| LENGTH OF STAY AND READMISSION RISK | 596 | ||
| THERAPY UTILIZATION | 596 | ||
| CLINICAL OUTCOMES | 597 | ||
| POTENTIAL FUTURE DIRECTIONS FOR UNITED STATES TRIALS | 598 | ||
| SUMMARY | 599 | ||
| REFERENCES | 600 | ||
| The Impact of Worsening Heart Failure in the United States | 603 | ||
| Key points | 603 | ||
| INTRODUCTION AND DEFINITIONS | 603 | ||
| ESTABLISHING A DEFINITION FOR WORSENING HEART FAILURE AS A CLINICAL TRIAL ENDPOINT | 604 | ||
| INITIAL DESCRIPTIONS OF THE INCIDENCE OF WORSENING HEART FAILURE AND ASSOCIATED OUTCOMES | 605 | ||
| WORSENING HEART FAILURE AS A TRIAL ENDPOINT | 605 | ||
| ASSOCIATION OF WORSENING HEART FAILURE WITH CLINICAL OUTCOMES | 605 | ||
| TREATMENT OF WORSENING HEART FAILURE | 611 | ||
| PREDICTION OF WORSENING HEART FAILURE | 611 | ||
| DEVELOPING THERAPEUTICS AND TREATMENT STRATEGIES THAT DECREASE WORSENING HEART FAILURE | 612 | ||
| SUMMARY | 613 | ||
| REFERENCES | 613 | ||
| End-of-life Heart Failure Care in the United States | 615 | ||
| Key points | 615 | ||
| INTRODUCTION | 615 | ||
| RESOURCE USE | 616 | ||
| PREDICTING DEATH | 616 | ||
| Hospitalized Setting | 616 | ||
| Ambulatory Setting | 616 | ||
| MANAGEMENT OPTIONS | 617 | ||
| Prolonging Life | 617 | ||
| Symptom Management | 618 | ||
| PALLIATIVE CARE AND HOSPICE | 619 | ||
| CHALLENGES AND SOLUTIONS | 619 | ||
| SUMMARY | 620 | ||
| REFERENCES | 620 | ||
| Epidemiology of Heart Failure in Europe | 625 | ||
| Key points | 625 | ||
| INTRODUCTION | 625 | ||
| PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE | 626 | ||
| Italian Network on Heart Failure Outcome Registry Findings | 626 | ||
| European Society of Cardiology Heart Failure Pilot Survey | 627 | ||
| European Society of Cardiology Heart Failure Long-Term Registry | 629 | ||
| AMBULATORY PATIENTS WITH CHRONIC HEART FAILURE | 632 | ||
| Italian Network on Heart Failure Outcome Registry Findings | 632 | ||
| European Society of Cardiology Heart Failure Pilot and Long-Term registries | 633 | ||
| SUMMARY | 634 | ||
| REFERENCES | 634 | ||
| Acute Heart Failure Syndromes in the Elderly | 637 | ||
| Key points | 637 | ||
| INTRODUCTION | 637 | ||
| CLINICAL PRESENTATION OF ELDERLY PATIENTS WITH ACUTE HEART FAILURE | 639 | ||
| COMORBIDITIES | 640 | ||
| MANAGEMENT OF ELDERLY PATIENTS WITH ACUTE HEART FAILURE | 640 | ||
| OUTCOMES OF ELDERLY PATIENTS WITH ACUTE HEART FAILURE | 641 | ||
| PREDICTORS OF CLINICAL OUTCOMES OF ELDERLY PATIENTS WITH ACUTE HEART FAILURE | 641 | ||
| COMPARISON OF THE EUROPEAN AND NORTH AMERICAN EXPERIENCE IN ELDERLY WITH ACUTE HEART FAILURE | 643 | ||
| SUMMARY AND FUTURE DIRECTIONS | 643 | ||
| REFERENCES | 644 | ||
| Characteristics of Intensive Care in Patients Hospitalized for Heart Failure in Europe | 647 | ||
| Key points | 647 | ||
| INTRODUCTION | 647 | ||
| DATA SOURCE INFORMATION | 648 | ||
| INTENSIVE CARE UNIT ADMISSION RATES | 648 | ||
| BASELINE CHARACTERISTICS OF PATIENTS ADMITTED TO INTENSIVE CARE UNITS | 649 | ||
| IN-HOSPITAL THERAPIES AND INVASIVE PROCEDURES | 650 | ||
| INTENSIVE CARE UNIT OUTCOMES | 652 | ||
| INTENSIVE CARE UNIT TRIAGE | 653 | ||
| CLINICAL RESEARCH IN THE INTENSIVE CARE UNIT SETTING | 654 | ||
| EUROPEAN PERSPECTIVES ON TRAINING AND EDUCATION IN CRITICAL CARE | 654 | ||
| SUMMARY | 655 | ||
| REFERENCES | 655 |